Knee osteoarthritis: Long-term GLP-1RA therapy is disease-modifying

被引：0
|
作者：
Di Lellis, Maddalena Angela
机构：
来源：
AKTUELLE RHEUMATOLOGIE | 2024年 / 49卷 / 01期
关键词：
D O I：
10.1055/a-2183-6149
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Eine Gewichtsreduktion gilt als eine der ersten Ma ss nahmen bei Kniearthrose (KOA). Jungste Erkenntnisse deuten darauf hin, dass bei Diabetes mellitus Typ 2 empfohlene Glucagonlike-Peptid-1-Rezeptor-Agonisten (GLP-1RAs), die eine Gewichtsreduktion bewirken, eine geringe Verbesserung der von den Patienten berichteten Kurzzeit-Ergebnisse bewirken. Zhu et al. untersuchten, ob KOA-Patienten von einer GLP-1RA-Therapie profitieren konnen.
引用
收藏
页码：17 / 17
页数：1
相关论文
共 50 条
  • [21] Combination Therapy of Endoscopic Gastric Remodeling with GLP-1RA for the Treatment of MASLD
    Jirapinyo, Pichamol
    Jaroenlapnopparat, Aunchalee
    Zucker, Stephen D.
    Thompson, Christopher C.
    [J]. OBESITY SURGERY, 2024, 34 (05) : 1471 - 1478
  • [22] Long-term effect of delaying disease-modifying therapy in patients with multiple sclerosis due to pregnancy planning
    Makkawi, Seraj
    Lavorato, Dina
    Greenfield, Jamie
    Parpal, Helene
    Metz, Luanne
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2018, 24 (02) : NP14 - NP14
  • [23] Combination Therapy of Endoscopic Gastric Remodeling with GLP-1RA for the Treatment of MASLD
    Pichamol Jirapinyo
    Aunchalee Jaroenlapnopparat
    Stephen D. Zucker
    Christopher C. Thompson
    [J]. Obesity Surgery, 2024, 34 : 1471 - 1478
  • [24] Knee Osteoarthritis-How Close Are We to Disease-Modifying Treatment: Emphasis on Metabolic Type Knee Osteoarthritis
    Lambova, Sevdalina Nikolova
    [J]. LIFE-BASEL, 2023, 13 (01):
  • [25] Disease-modifying drugs prevent long-term progression in multiple sclerosis patients
    Bergamaschi, R.
    Tavazzi, E.
    Quaglini, S.
    Poloni, G.
    Romani, A.
    Persico, A.
    Crivelli, P.
    Crabbio, M.
    Montomoli, C.
    Di Stefano, A. L.
    Bastianello, S.
    Cosi, V.
    [J]. MULTIPLE SCLEROSIS, 2007, 13 : S90 - S90
  • [26] No difference among disease-modifying drugs for the long-term treatment of multiple sclerosis
    Rolak, Loren A.
    Bejaoui, Khemissa
    Matti, Charmaine
    Foss, Dawn
    [J]. ANNALS OF NEUROLOGY, 2008, 64 : S59 - S59
  • [27] Disease-Modifying Agents in the Treatment of Multiple Sclerosis: A Review of Long-Term Outcomes
    Katrych, Oleksandra
    Simone, Tessa M.
    Azad, Shara
    Mousa, Shaker A.
    [J]. CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS, 2009, 8 (06) : 512 - 519
  • [28] Long-term efficacy and safety of a repeat treatment course of rituximab in ra patients with an inadequate response to disease-modifying antirheumatic drugs
    Emery, P.
    Bykerk, V. P.
    Ferraccioli, G.
    Udell, J.
    van Vollenhoven, R. F.
    Rowe, K.
    Agarwal, S.
    Shaw, T.
    [J]. JOURNAL OF RHEUMATOLOGY, 2007, 34 (07) : 1611 - 1612
  • [29] Is conventional radiography suitable for evaluation of a disease-modifying drug in patients with knee osteoarthritis?
    Mazzuca, SA
    Brandt, KD
    Katz, BP
    [J]. OSTEOARTHRITIS AND CARTILAGE, 1997, 5 (04) : 217 - 226
  • [30] Development of a Disease-Modifying OA Drug (DMOAD) in Knee Osteoarthritis: The Example of Sprifermin
    Marhardt, K.
    Muurahainen, N.
    [J]. DRUG RESEARCH, 2015, 65 : S13 - S13
12345